Biostate AI Raises $12M In Series A Funding Led By Accel

Biotech startup Biostate AI has raised $12 million in a Series A funding round led by Accel.

Gaingels, Mana Ventures, InfoEdge Ventures, as well as returning backers Matter Venture Partners, Vision Plus Capital, and Catapult Ventures also participated in this round.

The AI startup will use the new funding to make precision medicine more accessible, starting with RNA sequencing (RNAseq) services for molecular research in the US.

Read also- Jason Kothari’s New Startup Mythik Raises $15 Million In Seed Round

“Rather than solve the diagnostics and therapeutics as separate, siloed problems for each disease, we believe that the modern and future AI can be general purpose to understand and help cure every disease. Every diagnostic I’ve built was about moving the answer closer to the patient. Biostate takes the biggest leap yet by making the whole transcriptome affordable,” said Zhang, Co-founder and CEO of Biostate AI.

“Just as ChatGPT transformed language understanding by learning from trillions of words, we're learning the molecular language of human disease from billions of RNA expressions from millions of samples. We’re doing for molecular medicine what large language models did for text—scaling the raw data so the algorithms can finally shine,” said Gopinath, Co-founder and CTO of Biostate AI, and a former MIT assistant professor.

“Biostate is building the foundation model for molecular medicine by pairing deep wet lab innovation with AI to unlock RNAseq at unprecedented scale and affordability. Just as OpenAI used massive datasets to decode language, Biostate is decoding the molecular signals that govern human health," said Shekhar Kirani, Partner at Accel.

About Biostate AI

Founded in 2023 by David Zhang and Ashwin Gopinath, the Houston, Texas-based Biostate AI is using generative AI to predict how diseases will progress and how patients will respond to treatments, based on RNA sequencing data.

Currently, the company is focused on making RNA sequencing easier and more affordable, while building AI models to help doctors make better decisions. By combining lab techniques with AI, Biostate AI aims to lower costs, simplify processes, and help researchers produce consistent, high-quality data at scale.

Biostate AI has raised over $20 million so far and is growing its customer base through 100+ pilot projects focused on different diseases, like leukemia (with Cornell) and multiple sclerosis (with the Accelerated Cure Project). 

Since launching its services six months ago, the company says it has processed over 10,000 RNA sequencing samples for more than 150 partners and clients.

Startup Funding News: Your Gateway to Every Funding Update.

Latest Startup News: Stay updated with the latest startup news and trends. Your go-to source for startup ecosystem updates.

Startup Stories: Discover inspiring tales of startups overcoming challenges, and achieving success.